Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.
| Revenue (TTM) | $19.48B |
| Gross Profit (TTM) | $5.15B |
| EBITDA | $2.70B |
| Operating Margin | 9.63% |
| Return on Equity | 7.84% |
| Return on Assets | 3.94% |
| Revenue/Share (TTM) | $35.66 |
| Book Value | $27.69 |
| Price-to-Book | 0.84 |
| Price-to-Sales (TTM) | 0.63 |
| EV/Revenue | 1.034 |
| EV/EBITDA | 5.89 |
| Quarterly Earnings Growth (YoY) | -35.40% |
| Quarterly Revenue Growth (YoY) | 1.10% |
| Shares Outstanding | $519.02M |
| Float | $387.27M |
| % Insiders | 0.12% |
| % Institutions | 10.27% |
Volatility is currently expanding
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported broadly stable third-quarter revenue and a decline in operating income as reimbursement pressures and inflation weighed on results, while the company continued to advance its U.S. rollout of high-volume hemodiafiltration technology and execute its share repurchase program.
Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript
Fresenius Medical cuts top end of 2026 profit outlook
Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.
FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
These stocks have economic moats and look attractive today.
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FMS and any ticker you trade — then tracks every position and per-strategy win rate.
